This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Arthur Levin, PhD
Chief Scientific Officer at Avidity Biosciences

Profile

Arthur Levin is a key opinion leader in the RNA therapeutics field. He serves as the CSO at Avidity Biosciences. Previously, he held Senior levels positions at mRiragen, Santaris Pharma, and Ionis Pharmaceuticals. He played key roles in developing numerous of oligonucleotides including the first approved antisense drugs and the first microRNA-targeted therapeutic in clinical trials. He has three decades of experience in drug development from discovery through drug registration. Dr. Levin has published over 60 scientific articles and several of the most cited reviews in the field. He is on the scientific advisory boards of multiple institutions. Art received a doctorate in toxicology from the University of Rochester.

Agenda Sessions

  • Keynote Introduction by Session Chair and KEYNOTE PRESENTATION with Live Q&A -Antibody-siRNA Conjugates

    14:45
  • SESSION NAME: Safety Issues Related to Chemically Modified Oligos and Conjugates SESSION CHAIR:

    On Demand
  • Safety Issues Related to Chemically Modified Oligos and Conjugates

    16:30